Transforming Lives
Pioneering Enzyme Replacement Therapies for lysosomal storage diseases, using AI and synthetic biology to meet patients' unmet clinical needs.

About ZYTHERA
Next-generation enzyme replacement therapies for lysosomal storage diseases.
ZYTHERA is at the forefront of developing groundbreaking treatments for lysosomal storage diseases (LSDs), a diverse group rare metabolic disorders caused by enzyme deficiencies that lead to the accumulation of harmful substances in cells. Our mission is to transform the lives of patients by delivering highly effective and innovative enzyme replacement therapies (ERT).
We are committed to researching, developing, and commercializing state-of-the-art enzyme replacement therapies that address the unmet medical needs of those suffering from lysosomal storage diseases. Our focus is on delivering therapies that are not only safe and effective but also accessible to patients worldwide.
Our platform
Transforming lives through Advanced Enzyme Replacement Therapies
The ZYTHERA platform combines generative artificial intelligence for protein engineering, with a high-throughput microbial screening platform and downstream mammalian biologics production system to move from computational design to lead candidate identification in as little as 4-weeks.

Our propietary generative AI model uses protein sequence information to learn high-order amino acid relationships to design variant libraries of a target enzyme. Our variants are prioritized using our in-silico characterisation workflows to bring into the lab the most promising candidates.
We have developed a highly efficient, microliter-scale, protein screening platform based on P. pastoris, a widely used yeast in the biotech industry, which allows us to screen hundreds of enzymes in as little as 2 weeks.

Our Chinese Hamster Ovary (CHO) system integrates landing pads at genomic loci, which are designed to ensure single copy genomic integration of target enzymes to facilitate stable production of proteins with human-like biochemical properties.
Our Team
Experts in Next-generation Therapeutics Engineering








Research
Our ground-breaking research
ZYTHERA stems from ground-breaking research conducted in the Stracquadanio and Rosser lab at the University of Edinburgh and published in international, high-impact, peer-reviewed journals

Dirichlet latent modelling enables effective learning and sampling of the functional protein design space
Lobzaev, E. and Stracquadanio, G., 2024. Nature Communications, 15(1), p.9309.

Protein engineering using variational free energy approximation
Lobzaev, E., Herrera, M.A., Kasprzyk, M. and Stracquadanio, G., 2024. Nature Communications, 15(1), p.10447.